Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial.

Plain-language guide to PMID 29891957 (2018): open-label randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 29891957
Journal: Scientific reports
Year: 2018
Study type: Randomized Controlled Trial
Authors: Sharma SK et al. (11 authors)
DOI: 10.1038/s41598-018-26990-5

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

The researchers evaluated the impact of intensive smoking cessation activities as an adjunct to anti-tuberculosis treatment on patient-related treatment outcomes.

The primary outcomes were change in TBscore at 24-weeks and culture conversion at 8-weeks.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

In this open-label, randomised controlled trial, self-reporting smokers with pulmonary tuberculosis who initiated standard anti-tuberculosis treatment were randomised to either nicotine replacement therapy and behaviour change counselling (n = 400) or counselling alone (n = 400) provided at baseline and two follow-up visits.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Everyone knew when Therapeutic nicotine (patch, non-peptide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

The researchers evaluated the impact of intensive smoking cessation activities as an adjunct to anti-tuberculosis treatment on patient-related treatment outcomes.

The primary outcomes were change in TBscore at 24-weeks and culture conversion at 8-weeks.

Topics PubMed links to this paper include Antitubercular Agents, Behavior Therapy, Combined Modality Therapy, Counseling, Nicotinic Agonists, Smoking Cessation Agents and Tuberculosis, Pulmonary.

What This Means in Plain Language

The paper is a randomized and open-label study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2018 (Scientific reports), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.